48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank

Norges Bank purchased a new stake in Rapport Therapeutics (NASDAQ:RAPP) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 48,452 shares of the company’s stock, valued at approximately $860,000. Norges Bank owned approximately 0.13% of Rapport Therapeutics at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of RAPP. JPMorgan Chase & Co. boosted its position in Rapport Therapeutics by 77.8% in the fourth quarter. JPMorgan Chase & Co. now owns 7,170 shares of the company’s stock valued at $127,000 after buying an additional 3,137 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Rapport Therapeutics in the 4th quarter worth approximately $34,000. Swiss National Bank bought a new stake in Rapport Therapeutics during the 4th quarter worth approximately $319,000. New York State Common Retirement Fund bought a new stake in Rapport Therapeutics during the 4th quarter worth approximately $62,000. Finally, Jennison Associates LLC acquired a new stake in Rapport Therapeutics during the 4th quarter valued at $1,105,000.

Wall Street Analysts Forecast Growth

RAPP has been the subject of several research reports. Citizens Jmp started coverage on shares of Rapport Therapeutics in a research report on Tuesday, April 8th. They issued a “mkt outperform” rating for the company. JMP Securities began coverage on shares of Rapport Therapeutics in a research note on Tuesday, April 8th. They set a “market outperform” rating and a $28.00 price target on the stock. Four investment analysts have rated the stock with a buy rating, According to MarketBeat, Rapport Therapeutics has a consensus rating of “Buy” and an average price target of $32.67.

Rapport Therapeutics Stock Performance

Shares of Rapport Therapeutics stock opened at $9.26 on Friday. Rapport Therapeutics has a 52-week low of $6.43 and a 52-week high of $29.74. The business’s 50 day simple moving average is $11.16 and its 200 day simple moving average is $17.11. The firm has a market cap of $337.95 million and a PE ratio of -0.67.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, Director Wendy B. Young purchased 6,000 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average price of $10.21 per share, for a total transaction of $61,260.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $61,260. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Troy A. Ignelzi acquired 9,900 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was acquired at an average cost of $10.10 per share, with a total value of $99,990.00. Following the completion of the transaction, the chief financial officer now owns 9,900 shares of the company’s stock, valued at approximately $99,990. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.